These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1443 related items for PubMed ID: 12538684

  • 21. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I, Wang L, Wells AD, Ye Q, Han R, Dorf ME, Kuziel WA, Rollins BJ, Chen L, Hancock WW.
    J Immunol; 2003 Dec 15; 171(12):6929-35. PubMed ID: 14662900
    [Abstract] [Full Text] [Related]

  • 22. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
    Gu T, Zhu YB, Chen C, Li M, Chen YJ, Yu GH, Ge Y, Zhou SY, Zhou H, Huang Y, Qiu YH, Zhang XG.
    Cell Mol Immunol; 2008 Feb 15; 5(1):33-9. PubMed ID: 18318992
    [Abstract] [Full Text] [Related]

  • 23. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
    Jiao Q, Liu C, Li W, Li W, Fang F, Qian Q, Zhang X.
    Clin Exp Immunol; 2017 Jun 15; 188(3):420-429. PubMed ID: 28052400
    [Abstract] [Full Text] [Related]

  • 24. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.
    Schreiner B, Bailey SL, Shin T, Chen L, Miller SD.
    Eur J Immunol; 2008 Oct 15; 38(10):2706-17. PubMed ID: 18825752
    [Abstract] [Full Text] [Related]

  • 25. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
    Menke J, Lucas JA, Zeller GC, Keir ME, Huang XR, Tsuboi N, Mayadas TN, Lan HY, Sharpe AH, Kelley VR.
    J Immunol; 2007 Dec 01; 179(11):7466-77. PubMed ID: 18025191
    [Abstract] [Full Text] [Related]

  • 26. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
    He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH.
    J Immunol; 2004 Oct 15; 173(8):4919-28. PubMed ID: 15470033
    [Abstract] [Full Text] [Related]

  • 27. Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.
    Lages CS, Lewkowich I, Sproles A, Wills-Karp M, Chougnet C.
    Aging Cell; 2010 Oct 15; 9(5):785-98. PubMed ID: 20653631
    [Abstract] [Full Text] [Related]

  • 28. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
    Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, Sharpe AH, Umetsu DT, Dekruyff RH.
    Mucosal Immunol; 2010 Jan 15; 3(1):81-91. PubMed ID: 19741598
    [Abstract] [Full Text] [Related]

  • 29. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation.
    Pfistershammer K, Klauser C, Pickl WF, Stöckl J, Leitner J, Zlabinger G, Majdic O, Steinberger P.
    Eur J Immunol; 2006 May 15; 36(5):1104-13. PubMed ID: 16598819
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism.
    Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, Tsushima F, Hoshino T, Aizawa H, Akiba H, Pardoll D, Hara N, Yagita H, Azuma M, Nakanishi Y.
    J Immunol; 2004 Feb 15; 172(4):2530-41. PubMed ID: 14764726
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Differential binding properties of B7-H1 and B7-DC to programmed death-1.
    Youngnak P, Kozono Y, Kozono H, Iwai H, Otsuki N, Jin H, Omura K, Yagita H, Pardoll DM, Chen L, Azuma M.
    Biochem Biophys Res Commun; 2003 Aug 01; 307(3):672-7. PubMed ID: 12893276
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.
    Jurado JO, Alvarez IB, Pasquinelli V, Martínez GJ, Quiroga MF, Abbate E, Musella RM, Chuluyan HE, García VE.
    J Immunol; 2008 Jul 01; 181(1):116-25. PubMed ID: 18566376
    [Abstract] [Full Text] [Related]

  • 36. siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.
    Breton G, Yassine-Diab B, Cohn L, Boulassel MR, Routy JP, Sékaly RP, Steinman RM.
    J Clin Immunol; 2009 Sep 01; 29(5):637-45. PubMed ID: 19562472
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
    Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ.
    Immunity; 2007 Jul 01; 27(1):111-22. PubMed ID: 17629517
    [Abstract] [Full Text] [Related]

  • 39. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Blank C, Gajewski TF, Mackensen A.
    Cancer Immunol Immunother; 2005 Apr 01; 54(4):307-14. PubMed ID: 15599732
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 73.